source
- Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chainAfter committing $55 billion last year to bolster U.S. manufacturing capabilities, Johnson & Johnson is making changes to its pharmaceutical supply chain.BioSpace · 16d ago↗ source
- Celcuity gains FDA approval for closely watched breast cancer drugStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.BioPharma Dive · 16d ago↗ source
- Merck ADC, in China study, shows potential to replace chemo in lung cancerThe results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.